Welltower, Inc.: Barclays cuts target price to $246 from $259
WELL•Barclays cut its target price for Welltower to $246 from $259.
Related News
Tilray Medical wins INFARMED approval for in-house EU-GMP quality testing at Portugal facility
TLRY•
Bitmine joins Russell 1000 Large-Cap index
BMNR•
Scinai expands CDMO business with $5.1 million development and clinical manufacturing agreement
SCNI•
First Majestic suspends NAFTA arbitration against Mexico as settlement framework advances
AG•
D-Wave extends quantum chip manufacturing collaboration with SkyWater under multi-year agreement
QBTS•